North America Carrier Screening Market Poised for Growth Through 2033 as Advanced Genetic Technologies and Preventive Healthcare Demand Expand Opportunities
Dublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "North America Carrier Screening Market Size, Share & Industry Analysis Report by Type, Technology, End-use, Medical Conditions, Country Outlook and Forecast, 2026-2033" has been added to ResearchAndMarkets.com's offering.
North America Carrier Screening Market to Reach USD 1.4 Billion by 2032, Driven by Expanded Genetic Testing and Reproductive Health Planning
The North America carrier screening market is projected to reach USD 1.4 billion by 2032, expanding at a compound annual growth rate of 11.8% during 2026-2033. Market growth is being supported by advances in genetic science, prenatal care, molecular diagnostics, bioinformatics, and next-generation sequencing.
Carrier screening has progressed from limited testing for selected hereditary conditions and high-risk populations to broader, more inclusive screening models. The adoption of polymerase chain reaction, microarrays, and DNA sequencing has increased the number of inherited conditions that laboratories can assess while improving testing accuracy and clinical utility. The transition from ethnicity-based screening to expanded and pan-ethnic approaches is also influencing adoption across prenatal care, fertility services, and preventive healthcare.
Rising awareness of inherited diseases, declining sequencing costs, stronger integration of genomics into clinical workflows, and growing demand for reproductive health planning are key North America carrier screening market trends. Healthcare providers increasingly use carrier screening for preconception testing, prenatal care, fertility planning, population-risk assessment, and the identification of hereditary disease risks. Market participants are responding with broader gene panels, shorter turnaround times, AI-supported variant interpretation, secure data-management systems, and digital patient-engagement tools.
Type Outlook
By type, the market is segmented into expanded carrier screening and targeted disease screening. Expanded carrier screening dominated the market in 2025 and is expected to retain its leading position through 2033. The segment is forecast to reach USD 914.4 million by 2032, registering a CAGR of 11.5% during the forecast period. The targeted disease segment is projected to grow at a CAGR of 12.4% from 2026 to 2033.
Expanded screening benefits from demand for comprehensive panels that assess multiple inherited disorders in a single test and support carrier detection across diverse populations. Targeted disease screening remains important when testing decisions are guided by family history, known population risks, established clinical pathways, or cost considerations. Frequently evaluated conditions include cystic fibrosis, Tay-Sachs disease, and sickle cell disease.
Technology Outlook
The technology segments include DNA sequencing, polymerase chain reaction, microarrays, and other technologies. DNA sequencing led the North America carrier screening market in 2025 and is expected to remain dominant through 2033, with a projected CAGR of 11.2%. Its leadership reflects broad mutation-detection capabilities, high sensitivity, and compatibility with expanded carrier screening workflows.
Polymerase chain reaction is forecast to grow at a CAGR of 12.1% during 2026-2033 and remains widely used for targeted analysis of known variants. Microarrays support high-throughput screening of multiple established variants, while the other technology segment, projected to record a CAGR of 12.4%, includes digital PCR, specialized genotyping platforms, and emerging molecular diagnostic methods.
End-Use Outlook
By end use, the market comprises laboratories, hospitals, physician offices and clinics, and other facilities. Laboratories dominated in 2025 and are expected to maintain their leadership through 2033. The laboratory segment is projected to reach USD 609.5 million by 2032, growing at a CAGR of 11.2%.
Laboratory growth is supported by specialized sequencing infrastructure, high testing volumes, bioinformatics expertise, quality-control capabilities, and comprehensive variant interpretation. Hospitals are expected to register a CAGR of 12.0% as carrier screening becomes more closely integrated with prenatal care, reproductive medicine, maternal-fetal health, and clinical genetics. Physician offices and clinics are projected to post the highest CAGR of 12.7%, supported by patient education, preconception screening, sample collection, and referral services.
Medical Condition Outlook
The market is segmented by medical condition into cystic fibrosis, spinal muscular atrophy, sickle cell disease, Tay-Sachs disease, Gaucher disease, and other inherited conditions. Cystic fibrosis leads the segment due to established screening guidelines, strong clinician awareness, and routine inclusion in reproductive testing panels.
Spinal muscular atrophy screening is gaining importance as awareness and early detection initiatives expand. Sickle cell disease continues to generate demand through targeted testing and public health programs, while Tay-Sachs and Gaucher disease remain prominent in population-specific and expanded panels. Broader panels are also increasing testing coverage for rare metabolic, neuromuscular, and hereditary disorders.
Country Outlook
The United States dominated the North America carrier screening market in 2025 and is expected to maintain its leading position through 2033. The US market is projected to reach USD 1.1 billion by 2032, growing at a CAGR of 11.1%. Growth is supported by extensive sequencing infrastructure, adoption of expanded carrier screening, direct-to-consumer testing, digital health integration, and widespread use in fertility and prenatal care.
Canada is forecast to record a CAGR of 14.7% during 2026-2033, supported by demand for pan-ethnic screening, genomic testing adoption, ethical data governance, and digital genetic counseling. Mexico is expected to grow at a CAGR of 13.7% as access to screening panels improves and telemedicine-enabled counseling, reproductive health awareness, and clinical adoption increase.
Key Companies Profiled
North America Carrier Screening Market Segmentation
By Type: Expanded carrier screening and targeted disease screening.
By Technology: DNA sequencing, polymerase chain reaction, microarrays, and other technologies.
By End Use: Laboratories, hospitals, physician offices and clinics, and other end users.
By Medical Condition: Cystic fibrosis, spinal muscular atrophy, sickle cell disease, Tay-Sachs disease, Gaucher disease, and other medical conditions.
By Country: United States, Canada, Mexico, and the rest of North America.
Key Topics Covered:
Chapter 1. North America Market
1.1 Market Overview
1.2 Key Factors Impacting Market
1.2.1 Market Drivers
1.2.2 Market Restraints
1.2.3 Market Opportunities
1.2.4 Market Challenges
1.2.5 Market Trends
1.2.6 State of Competition
1.2.7 Market Consolidation
1.2.8 Key Customer Criteria
1.3 Product Life Cycle
1.4 Segmentation By Type
1.4.1 Expanded
1.4.2 Targeted Disease
1.5 Segmentation By Technology
1.5.1 DNA Sequencing
1.5.2 Polymerase Chain Reaction
1.5.3 Microarrays
1.5.4 Other Technology
1.6 Segmentation By End-use
1.6.1 Laboratories
1.6.2 Hospitals
1.6.3 Physician Offices &Clinics
1.6.4 Other End-use
1.7 Segmentation By Medical Condition
1.7.1 Cystic Fibrosis
1.7.2 Spinal Muscular Atrophy
1.7.3 Sickle Cell Disease
1.7.4 Tay-Sachs
1.7.5 Gaucher Disease
1.7.6 Other Medical Condition
1.8 Segmentation By Country
1.8.1 US
1.8.1.1 Segmentation By Type
1.8.1.1.1 Expanded
1.8.1.1.2 Targeted Disease
1.8.1.2 Segmentation By Technology
1.8.1.2.1 DNA Sequencing
1.8.1.2.2 Polymerase Chain Reaction
1.8.1.2.3 Microarrays
1.8.1.2.4 Other Technology
1.8.1.3 Segmentation By End-use
1.8.1.3.1 Laboratories
1.8.1.3.2 Hospitals
1.8.1.3.3 Physician Offices &Clinics
1.8.1.3.4 Other End-use
1.8.1.4 Segmentation By Medical Condition
1.8.1.4.1 Cystic Fibrosis
1.8.1.4.2 Spinal Muscular Atrophy
1.8.1.4.3 Sickle Cell Disease
1.8.1.4.4 Gaucher Disease
1.8.1.4.5 Tay-Sachs
1.8.1.4.6 Other Medical Condition
1.8.2 Canada
1.8.2.1 Segmentation By Type
1.8.2.1.1 Expanded
1.8.2.1.2 Targeted Disease
1.8.2.2 Segmentation By Technology
1.8.2.2.1 DNA Sequencing
1.8.2.2.2 Polymerase Chain Reaction
1.8.2.2.3 Microarrays
1.8.2.2.4 Other Technology
1.8.2.3 Segmentation By End-use
1.8.2.3.1 Laboratories
1.8.2.3.2 Hospitals
1.8.2.3.3 Physician Offices &Clinics
1.8.2.3.4 Other End-use
1.8.2.4 Segmentation By Medical Condition
1.8.2.4.1 Cystic Fibrosis
1.8.2.4.2 Spinal Muscular Atrophy
1.8.2.4.3 Sickle Cell Disease
1.8.2.4.4 Gaucher Disease
1.8.2.4.5 Tay-Sachs
1.8.2.4.6 Other Medical Condition
1.8.3 Mexico
1.8.3.1 Segmentation By Type
1.8.3.1.1 Expanded
1.8.3.1.2 Targeted Disease
1.8.3.2 Segmentation By Technology
1.8.3.2.1 DNA Sequencing
1.8.3.2.2 Polymerase Chain Reaction
1.8.3.2.3 Microarrays
1.8.3.2.4 Other Technology
1.8.3.3 Segmentation By End-use
1.8.3.3.1 Laboratories
1.8.3.3.2 Hospitals
1.8.3.3.3 Physician Offices &Clinics
1.8.3.3.4 Other End-use
1.8.3.4 Segmentation By Medical Condition
1.8.3.4.1 Cystic Fibrosis
1.8.3.4.2 Spinal Muscular Atrophy
1.8.3.4.3 Sickle Cell Disease
1.8.3.4.4 Gaucher Disease
1.8.3.4.5 Tay-Sachs
1.8.3.4.6 Other Medical Condition
1.8.4 Rest of North America
1.8.4.1 Segmentation By Type
1.8.4.1.1 Expanded
1.8.4.1.2 Targeted Disease
1.8.4.2 Segmentation By Technology
1.8.4.2.1 DNA Sequencing
1.8.4.2.2 Polymerase Chain Reaction
1.8.4.2.3 Microarrays
1.8.4.2.4 Other Technology
1.8.4.3 Segmentation By End-use
1.8.4.3.1 Laboratories
1.8.4.3.2 Hospitals
1.8.4.3.3 Physician Offices &Clinics
1.8.4.3.4 Other End-use
1.8.4.4 Segmentation By Medical Condition
1.8.4.4.1 Cystic Fibrosis
1.8.4.4.2 Spinal Muscular Atrophy
1.8.4.4.3 Sickle Cell Disease
1.8.4.4.4 Gaucher Disease
1.8.4.4.5 Tay-Sachs
1.8.4.4.6 Other Medical Condition
Chapter 2. Company Snapshots
2.1 Natera, Inc.
2.1.1 Business Overview
2.1.2 Key Information
2.1.3 Company Focus on Carrier Screening Market
2.1.4 Strategic Insights
2.1.5 Strategy Deployed
2.1.6 Product &Service Portfolio
2.1.7 Representative Products
2.1.8 Capability Overview
2.1.9 Technology &Innovation Focus
2.1.10 SWOT Analysis
2.1.11 Customers / End Users
2.1.12 Competitive Positioning
2.1.13 Key Differentiators
2.1.14 Portfolio Matrix
2.1.15 Analyst View
2.1.16 Future Outlook
2.2 Myriad Genetics, Inc.
2.2.1 Business Overview
2.2.2 Key Information
2.2.3 Company Focus on Carrier Screening Market
2.2.4 Strategic Insights
2.2.5 Strategy Deployed
2.2.6 Product &Service Portfolio
2.2.7 Representative Products
2.2.8 Capability Overview
2.2.9 Technology &Innovation Focus
2.2.10 SWOT Analysis
2.2.11 Customers / End Users
2.2.12 Competitive Positioning
2.2.13 Key Differentiators
2.2.14 Portfolio Matrix
2.2.15 Analyst View
2.2.16 Future Outlook
2.3 Labcorp Holdings Inc.
2.3.1 Business Overview
2.3.2 Key Information
2.3.3 Company Focus on Carrier Screening Market
2.3.4 Strategic Insights
2.3.5 Strategy Deployed
2.3.6 Product &Service Portfolio
2.3.7 Representative Products / Services
2.3.8 Capability Overview
2.3.9 Technology &Innovation Focus
2.3.10 SWOT Analysis
2.3.11 Customers / End Users
2.3.12 Competitive Positioning
2.3.13 Key Differentiators
2.3.14 Portfolio Matrix
2.3.15 Analyst View
2.3.16 Future Outlook
2.4 Quest Diagnostics Incorporated
2.4.1 Business Overview
2.4.2 Key Information
2.4.3 Company Focus on Carrier Screening Market
2.4.4 Strategic Insights on Carrier Screening Market
2.4.5 Strategy Deployed for Carrier Screening Market
2.4.6 Product &Service Portfolio
2.4.7 Representative Products / Services
2.4.8 Capability Overview
2.4.9 Technology &Innovation Focus
2.4.10 SWOT Analysis
2.4.11 Customers / End Users
2.4.12 Competitive Positioning
2.4.13 Key Differentiators
2.4.14 Portfolio Matrix
2.4.15 Analyst View
2.4.16 Future Outlook
2.5 Fulgent Genetics, Inc.
2.5.1 Business Overview
2.5.2 Key Information
2.5.3 Company Focus on Carrier Screening Market
2.5.4 Strategic Insights
2.5.5 Strategy Deployed
2.5.6 Product &Service Portfolio
2.5.7 Representative Products / Services
2.5.8 Capability Overview
2.5.9 Technology &Innovation Focus
2.5.10 SWOT Analysis
2.5.11 Customers / End Users
2.5.12 Competitive Positioning
2.5.13 Key Differentiators
2.5.14 Portfolio Matrix
2.5.15 Analyst View
2.5.16 Future Outlook
2.6 Tempus AI, Inc.
2.6.1 Business Overview
2.6.2 Key Information
2.6.3 Company Focus on Carrier Screening Market
2.6.4 Strategic Insights
2.6.5 Strategy Deployed for Carrier Screening Market
2.6.6 Product &Service Portfolio
2.6.7 Representative Products / Services
2.6.8 Capability Overview
2.6.9 Technology &Innovation Focus
2.6.10 SWOT Analysis
2.6.11 Customers / End Users
2.6.12 Competitive Positioning
2.6.13 Key Differentiators
2.6.14 Portfolio Matrix
2.6.15 Analyst View
2.6.16 Future Outlook
2.7 OPKO Health, Inc.
2.7.1 Business Overview
2.7.2 Company Profile
2.7.3 Company Focus on Carrier Screening Market
2.7.4 Strategic Insights on Carrier Screening Market
2.7.5 Strategy Deployed for Carrier Screening Market
2.7.6 Product &Service Portfolio
2.7.7 Representative Products / Services
2.7.8 Capability Overview
2.7.9 Technology &Innovation Focus
2.7.10 SWOT Analysis
2.7.11 Customers / End Users
2.7.12 Competitive Positioning
2.7.13 Key Differentiators
2.7.14 Portfolio Matrix
2.7.15 Analyst View
2.7.16 Future Outlook
2.8 GeneDx Holdings Corp.
2.8.1 Business Overview
2.8.2 Key Information
2.8.3 Company Focus on Carrier Screening Market
2.8.4 Strategic Insights
2.8.5 Strategy Deployed
2.8.6 Product &Service Portfolio
2.8.7 Representative Products / Services
2.8.8 Capability Overview
2.8.9 Technology &Innovation Focus
2.8.10 SWOT Analysis
2.8.11 Customers / End Users
2.8.12 Competitive Positioning
2.8.13 Key Differentiators
2.8.14 Portfolio Matrix
2.8.15 Analyst View
2.8.16 Future Outlook
2.9 Eurofins Scientific SE
2.9.1 Business Overview
2.9.2 Key Information
2.9.3 Company Focus on Carrier Screening Market
2.9.4 Strategic Insights on Carrier Screening Market
2.9.5 Strategy Deployed for Carrier Screening Market
2.9.6 Product &Service Portfolio
2.9.7 Representative Products / Services
2.9.8 Capability Overview
2.9.9 Technology &Innovation Focus
2.9.10 SWOT Analysis
2.9.11 Customers / End Users
2.9.12 Competitive Positioning
2.9.13 Key Differentiators
2.9.14 Portfolio Matrix
2.9.15 Analyst View
2.9.16 Future Outlook
2.10 MedGenome Labs Ltd.
2.10.1 Business Overview
2.10.2 Key Information
2.10.3 Company Focus on Carrier Screening Market
2.10.4 Strategic Insights
2.10.5 Strategy Deployed
2.10.6 Product &Service Portfolio
2.10.7 Representative Products / Services
2.10.8 Capability Overview
2.10.9 Technology &Innovation Focus
2.10.10 SWOT Analysis
2.10.11 Customers / End Users
2.10.12 Competitive Positioning
2.10.13 Key Differentiators
2.10.14 Portfolio Matrix
2.10.15 Analyst View
2.10.16 Future Outlook
Companies Featured
Natera, Inc.
Myriad Genetics, Inc.
Labcorp Holdings Inc. (including select Invitae assets)
Quest Diagnostics Incorporated
Fulgent Genetics, Inc.
Tempus AI, Inc. (Ambry Genetics)
OPKO Health, Inc. (BioReference / GenPath)
GeneDx Holdings Corp.
Eurofins Scientific SE
MedGenome Labs Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/3mzyfm
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.